Federal Court MDL: IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation
(Posted by Tom Lamb at Drug Injury Watch)
In December 2025, the U.S. Judicial Panel on Multidistrict Litigation (JPML) issued a ruling that keeps the NAION eye side effect for Ozempic and Mounjaro lawsuits filed in the federal court system separate from other injuries associated with those two injectable medicines and others in the GLP-1 agonists class of drugs — which includes Wegovy and Rybelsus as well as Zepbound.
From a December 15, 2025, Reuters news report, “Lawsuits claiming Ozempic, other GLP-1s led to blindness become second mass litigation over the drugs“, we get some information about this important development for lawsuits concerning the NAION eye side effect for Ozempic and Mounjaro:
A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly alleging patients lost some or all of their eyesight while taking the companies’ blockbuster weight loss drugs before [U.S. District Judge Karen Marston] in Pennsylvania.
The lawsuits in the new MDL allege the drugs… can trigger non-arteritic anterior ischemic optic neuropathy [(NAION)], a condition that occurs when blood flow to the optic nerve is blocked or reduced, which can lead to blindness.
The drugs belong to a class of injectable drugs known as GLP-1 agonists…. They were originally developed to treat diabetes but versions of the drugs are now also used for weight loss. They are widely prescribed in the U.S., with an August U.S. Centers for Disease Control and Prevention study finding that more than one in four adults with diabetes used one.
The [new MDL] case is IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, case number 3163.
NAION Eye Side Effect for Ozempic, Wegovy, and Rybelsus
Here are some earlier articles about the NAION eye side effect for Ozempic, Wegovy, and Rybelsus that are available on our DrugInjuryLaw.com website:
- Ozempic Vision Loss Claims Compensation Payments Made in 2025
- Ozempic NAION Rate Higher in Recent 2025 Medical Study
- Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs
- Link Between Ozempic and NAION Also Involves the Eye Disorder AION
- Ozempic Blindness Legal Cases Filed Against Novo Nordisk in April 2025
- Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
- Ozempic Eye Problems Caused by Semaglutide-Related NAION
- Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect
- Ozempic Side Effects Include Eye Problems With Possible Vision Loss
__________________________________________________________________
Ozempic / Wegovy / Rybelsus
Free Case Evaluation
Strictly Confidential, No Obligation.
_________________________________
Mounjaro / Zepbound
Free Case Evaluation
Strictly Confidential, No Obligation.
__________________________________________________________________
NAION Eye Side Effect for Mounjaro and Zepbound
Here are some earlier articles about the NAION eye side effect for Mounjaro and Zepbound that are available on our DrugInjuryLaw.com website:
- Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs
- NAION With Tirzepatide-containing Drugs Mounjaro and Zepbound
For more than a year now, we have been investigating drug injury lawsuits for patients who have been diagnosed with the NAION eye side effect for Ozempic and Mounjaro.
Drug injury lawsuits involving Ozempic, Wegovy, or Rybelsus for patients with vision loss due to NAION would be filed against Novo Nordisk.
Drug injury lawsuits involving Moujaro or Zepbound for patients with vision loss due to NAION would be filed against Eli Lilly.
We point out that because there are no warnings about the NAION eye side effect for Ozempic and Mounjaro (as well as Wegovy, Rybelsus, and Zepbound) in their current drug labels, those drug injury cases would only be filed against the responsible pharmaceutical companies — and not against patients’ doctors.
These drug injury lawsuits seek legal compensation payments for the person suffering from a loss of vision or blindness due to NAION. We offer an online case evaluation service that is free and confidential, and without obligation:
Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form
Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form
Attorney Tom Lamb reviews each one of these online submissions. Or call 910-256-2971 to speak with him about your possible NAION eye side effect drug injury lawsuit.
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects
Drug Injury Case Evaluation – Free. Confidential. No Obligation.
Leave a Reply